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A B S T R A C T
Purpose: To assess the mortality related to epilepsy in Latin America.
Methods: We searched MEDLINE, EMBASE, and LILACS from inception to December 2013 for articles
evaluating mortality in patients with epilepsy in Latin America. Studies were included if they evaluated
any mortality outcome, included a population of subjects with recurrent seizures or epilepsy, and
contained original data analysis.
Results: The search strategy yielded 177 publications in MEDLINE and EMBASE, and 59 publications in
LILACS; of which 18 met inclusion criteria for our overall review of epilepsy and mortality in Latin
America. Most excluded studies did not report the mortality or lacked original data. We also included
two references obtained from 2 non-systematic reviews fulﬁlling our inclusion criteria, and able to
provide data for our analyses. Five studies reported Standardized Mortality Ratio (SMR), and
demonstrated that people with epilepsy had a higher risk of death than the general population. The
SMRs reported in two community-based studies were 1.34 and 2.45.
Conclusion: The information about mortality in epilepsy in Latin America is very scarce. Comparisons
cannot be made among studies due to methodological differences. More studies are needed.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Epilepsy is a potentially life-threatening condition,1 and there is
evidence of a higher prevalence and incidence in Latin America2
when compared with developed countries. Mortality in patients
with epilepsy is known to be considerably higher than in the
general population.3–11 Unfortunately, mortality data from devel-
oping countries has been difﬁcult to obtain because incidence
studies are difﬁcult to perform, death certiﬁcates are not very
reliable, autopsies are not easy to obtain, and the cause of death is
not usually known with certainty.12–14 Ideally, identiﬁcation of at
risk individuals is imperative so that strategies to prevent
mortality can be implemented. Furthermore, comparison of
epilepsy mortality data between countries could potentially
identify conditions that require speciﬁc regional treatment or
medical attention.* Corresponding author at: Epilepsy Programme, University Hospital, 339
Windermere Road, B10-118, London, Ontario N5A5A5, Canada.
Tel.: +1 519 6633464; fax: +1 519 6633498.
E-mail address: jburneo2@uwo.ca (J.G. Burneo).
http://dx.doi.org/10.1016/j.seizure.2014.09.012
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reTo examine if epilepsy increases the risk of dying in Latin
America, we reviewed cohort studies from this region that assessed
mortality in populations with epilepsy compared with that
expected in the general population.
2. Methods
2.1. Eligibility criteria
Type of studies: cohort studies of epilepsy cases from Latin
America, evaluating mortality. Latin America includes Central
America, South America, Mexico, and the Caribbean. No language
or publication date restrictions were imposed.
Type of population: cohorts of any age collected in a
community, neurology department, or epilepsy center were
included.
Type of exposure: cohorts were selected if epilepsy was deﬁned
in accordance with International League Against Epilepsy deﬁni-
tions and recommendations.
Primary outcome measures: presentation of the observed
number of deaths in people with epilepsy or of a calculated
standardized mortality ratio (SMR).
Secondary outcome measures: distribution of causes of death.served.
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tronic databases and scanning reference lists of articles. This search
was applied to MEDLINE (1946–present), EMBASE (1974–present) and
LILACS (1981–present). LILACS is the most important and comprehen-
sive index of scientiﬁc and technical literature of Latin America and the
Caribbean. The last search was run in December of 2013 (see
Appendix A for full electronic search strategy for each database).
Study selection: two reviewers performed eligibility assess-
ments independently. Any disagreement between the reviewers
was resolved by consensus. Studies were included if they met the
following criteria: (a) prospective or retrospective cohorts of
subjects with the diagnosis of epilepsy, (b) presentation of a
calculated standardized mortality ratio (SMR) or mortality rate
(MR), and (c) contained original data analysis. We excluded studies
evaluating mortality rates from epilepsy in the general population
obtained from death certiﬁcates, non-systematic reviews (with the
exception of using them to retrieve references not found in the
above mentioned databases), and duplicate publications.
Data collection process: one review author extracted the
following data from included studies and the second author
veriﬁed the extracted data: country, year of study start, cohort type
(prospective or retrospective), selected cases (incident or preva-
lent), source of cases (neurology department, epilepsy center, rural
community or urban community), study size, proportion of treated
people, age at study entry, years of follow-up, number of observed
deaths, SMR, causes of death.
3. Results
The search strategy yielded 192 publications in MEDLINE, 425
publications in EMBASE, and 415 publications in LILACS. After the
ﬁrst screening, 14 documents were read and critically reviewed.
Five ﬁnal articles were selected (Fig. 1).
3.1. Description of studies
Five references from ﬁve different countries were identiﬁed.
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Fig. 1. Flow of information through the diffurban. Both were retrospective studies and prevalent cases were
selected (Table 1). Interestingly, almost 45% of the patients in these
two studies saw remission of their epilepsy during the 8–10 years
of the follow-up even though, apparently, only 12% of the patients
had taken antiepileptic medications for more than one year.15
Three articles corresponded to selected populations with
epilepsy. All three were hospital-based,12,17,18 and in one of them
the data was obtained from an epilepsy center.18 All three had a
prospective design, although only one selected incident cases.12
Additionally, two of these articles were focused on young
populations17,18 (Table 1).
3.2. All causes of mortality
There were two community-based studies (Table 2). In the
urban community-based study in Argentina, the SMR was 2.45 and
the MR 17.86, while in the rural-community-based study in Bolivia
the SMR was 1.34 and the MR was 9.71. Age-speciﬁc SMRs were
available for the study done in Ecuador; while MRs were available
in the study done in Bolivia (Table 3). In regards to etiology, only
one study evaluated the mortality in patients with idiopathic
epilepsy and did not ﬁnd a signiﬁcantly increased risk of death
(Table 4), however patients with remote symptomatic epilepsy did
have an increased risk. In this last group of patients with
symptomatic epilepsy, 61% of cases at risk had neurocysticercosis
(NCC)-related epilepsy, and were living in rural areas.15 Further-
more, the single urban community-based study showed a MR of 40
per 1000 patient-year in the symptomatic epilepsy group, in whom
50% had tumor-related epilepsy.16
3.3. Cause-speciﬁc mortality
The most common cause of death in community based studies
corresponded to underlying disease-related deaths or epilepsy-
unrelated deaths (Table 5), although almost 25% of deaths had
unknown cause. In selected population-based studies, 20–42% of
the observed deaths were in relation with SUDEP, although only
7–14% of them were determined to be deﬁnitive cases. 
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Table 1
Summary of mortality studies.
Country Population Study design Case selection Start
of the
study
Years
of f/u
N Age at
entry
Proportion
of males
Proportion
treated
Proportion
of active
epilepsy at
the end
of study
Number of deaths
Observed Expected
Bolivia15 Rural community-
based
Retrospective Prevalent cases 1994 10 103 All ages 0.47 0.12 40/71 10 7.46
Argentina16 Urban community-
based
Retrospective Prevalent cases 1991 8 56 All ages NA NA 32/96 8 3.27
Ecuador12 Hospital-based Prospective Incident cases 1997 1.14a 379 All ages 0.56 NA NA 7 1.28
Brazil17 Hospital-based Prospective Prevalent cases 2000 10.9 1012 0–18 years 0.58 NA NA 16 NA
Chile18 Epilepsy center Prospective Incident + prevalent 1996 NA 695 0–19 years NA NA NA 16 NA
NA: not applicable/not available.
a Patient-year.
Table 2
All-cause mortality in community-based populations and selected populations. The
SMR obtained from the Bolivian study was adjusted for age, sex, and time period.
The SMR obtained from the studies done in Argentina and Ecuador was adjusted
only for sex and time period.
Studies SMR (95% CI) MR
Community-based Bolivia 1.34 (0.68–2.39) 9.71
Argentina 2.45 17.86
Hospital-based Ecuador 6.3 (2–10) 6.1
MR: mortality rate; SMR: standardized mortality rate.
Table 3
All-cause mortality in community-based populations and selected populations
according to age groups.
Studies 0–19 y 20–59 y >60 y
SMR (95% CI) MR SMR (95% CI) MR SMR (95% CI) MR
Community-based
Bolivia 4.29 17.24 50
Hospital-based
Ecuador 7.7 (1.9–15.9) 7.1 (0.6–18.3) 3.2 (0.01–9.5)
Brazil 5.6
Chile 3.21 (1.48–4.95)
SMR: standardized MR; MR: mortality rate; CI: conﬁdence interval; y: years of age.
Table 4
All-cause mortality in community-based populations and selected populations
according to epilepsy etiology.
Studies Idiopathic epilepsy Symptomatic remote
SMR (95% CI) MR SMR (95% CI) MR
Community-based
Ecuador 0.74 (0.2–1.8) 0.6 3 (1.2–6.3) 0.2
Argentina 0.12 0.4
Hospital-based
Brazil 0 0.05
SMR: standardized MR; MR: mortality rate; CI: conﬁdence interval.
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Mortality can be divided into deaths attributable to epilepsy
(epilepsy related), deaths from the pathology responsible for the
epilepsy, and deaths from unrelated conditions.19 Deaths due to
sudden unexpected death in epilepsy (SUDEP), status epilepticus
(SE), suicide, and accidents are considered to be epilepsy-related.20
Mortality in patients with epilepsy can be an indirect estimator
of the epilepsy severity and its public health impact.10 Differentmeasures to estimate mortality have been used. Case fatality refers
to the number of deaths divided by the number of patients with the
disease in the study population. It is inﬂuenced by the distribution
of prognostic factors and by differences in medical care. The
mortality rate (MR) is the number of deaths that occur in a deﬁned
population, in a speciﬁc time, divided by the person-years at risk in
that population. It is inﬂuenced by the incidence of epilepsy in a
population, the case fatality, and the age distribution of the
population. The standardized mortality ratio (SMR) is the ratio of
the observed number of deaths in a population with epilepsy in
comparison to the mortality rate in the general population,
adjusted by age and sex speciﬁc. Even though it may be difﬁcult to
compare SMRs between studies because the measure depends on
the mortality rate in the reference population,19 the use of SMRs is
considered to the best measure to report mortality.
Population-based cohorts assessing incident cases represent
the gold standard for studies on mortality. These cohorts allow for
an adequate and complete collection of data as well as the
observation throughout the patients’ lifespans.10 We did not ﬁnd
this type of cohort in our review, even though the studies of
Nicolleti et al. and Kochene et al. are very useful, considering that
are based in cohorts and report SMRs. Even though these 2 studies
had a different methodology, and comparison of SMRs has to be
done with caution, they demonstrated SMRs ranging from 1.34 to
2.45, and are relevant because they included patients from the
general population and probably a full spectrum of patients with
epilepsy (e.g. intractable and not intractable cases). The rates
reported in these studies are comparable to studies where speciﬁc
populations have been assessed such as the study in Rochester,
Minnesota.3 Limitations related to the use of cohorts for assessing
prevalence and the small number of cases in these studies should
be taken into account. Prevalence cohorts might underestimate
short-term mortality because the more serious cases die in the
early phase of the disease and are not included in the calculation of
deaths over the period of observation.10 Also, the median age of the
subjects included in the studies was not available, which would
allow us to have a better sense on the degree of heterogeneneity in
these cohorts.
Two hospital-based studies reported SMRs of 3.21 and 6.3,
which are higher than the rates reported by Nicolette and
Kochen.15,16 These kinds of studies are more likely to include
severe cases with respect to seizure frequency, duration of
epilepsy, and resistance to antiepileptic drug therapy than might
affect the results. Mortality rates based on death certiﬁcates in the
general population ranged from 0.9 to 4.6/100 000 person-year
with a potential temporal trend to decline. Based on a single
underlying cause of death listed on the death certiﬁcate, such
tabulations underestimate the number of deaths among
people with epilepsy. In addition, the presence of epilepsy is
Table 5
Cause-speciﬁc mortality in community-based populations and selected populations.
Studies Epilepsy-related deaths Underlying disease-related deaths Unrelated deaths Unknown
Deﬁnitive
SUDEP
Probable
SUDEP
Accidents Suicides SE Seizure-
related
Brain
tumor
Stroke Pneumonia Sepsis Other
Community-based
Bolivia 10.0% 10.0% 10.0% 50.0% 20.0%
Argentina 50.0% 25.0% 25.0%
Hospital-based
Ecuador 14.3% 28.6% 28.6% 14.3% 14.3%
Brazil 20.8% 15.1% 30.2% 17.0% 17.0%
Chile 6.7% 26.7% 53.3% 13.3%
SE: status epilepticus; SUDEP: sudden unexpected death in epilepsy.
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even when recorded, the accuracy of a diagnosis included on a
death certiﬁcates has been questioned.21 More epidemiological
studies exploring MR are required to support any trends.
SUDEP is probably the most common direct epilepsy-related
cause of death.14 Nashef has proposed the following deﬁnition:
Sudden, unexpected, witnessed or unwitnessed, non-traumatic
and non-drowning deaths in patients with epilepsy, with or
without evidence of a seizure and excluding documented status
epilepticus, in which post-mortem examination does not reveal a
toxicologic or anatomic cause of death.22 Thus, according to this
deﬁnition, necropsy is required for a deﬁnitive classiﬁcation. Only
two studies12,23 reported cases of deﬁnite SUDEP and only one of
them described the autopsy ﬁndings.12 These results reﬂect the
difﬁculty in obtaining autopsies in Latin American countries and
probably there is under- or over-estimation SUDEP. Furthermore,
according to Carpio et al.,12 less severe new-onset cases of epilepsy
are usually not managed in hospitals, affecting the distribution of
causes of death. One preliminary study from Brazil24 demonstrated
that SUDEP cases in children are related to chronic uncontrolled
epilepsy. Improved seizure control by treatment (pharmacological
or surgical) would seem to be one of the most important measures
to prevent SUDEP.
Status epilepticus (SE) is common in patients admitted to
hospitals in resource poor countries. Most studies on SE in these
countries describe convulsive status epilepticus (CSE), since non-
convulsive epilepticus is rarely detected in these regions, due to
the lack of resources (continuous EEG monitoring).25 Most CSE
have a known etiology (symptomatic), with the increased
incidence attributed to the increased incidence of infections.
Many hospitals in these countries, particularly those in rural areas
have few drugs to treat CSE, and many hospitals do not have
intensive care facilities such as ventilators or sufﬁcient health
personnel to provide optimal management. Hence, strong consid-
erations should be given to the training of health care providers as
well as the provision of necessary equipment so that they are able
to initiate therapies for CSE.
Despite the methodological difﬁculty comparing studies, it
seems that mortality in people with epilepsy in Latin America is
similar to the that reported in developed countries.8 Few studies
have been published and it is possible that studies from very poor
countries in Latin America could report higher rates. The lack of
standardized treatment programs, the economic problems than
might not guarantee the drug supply, the poor healthcare
infrastructure, and the distance difﬁculties of rural population,
may increase the mortality, but in the very few studies that have
reported, that is not seen.
Only one study evaluated the mortality in patients with
idiopathic epilepsy and did not ﬁnd a signiﬁcant increased risk
of death.15 Meanwhile, most deaths in the other studiescorresponded to symptomatic cases. The information about risk
factors for death has not been explored in Latin American studies.
This information needs more scrutiny in the future in order to
establish preventive measures.
Despite the main limitation of this study, which is the limited
data found in the literature, the studies reported in this review
provide interesting information about rates of mortality in Latin
America. Also, one has to be cautious interpreting the different
SMRs, because of the different methodologies used in the studies
included in this review. But, these studies reported SMRs
indicating that epilepsy has a higher risk of death than the general
population, but not higher than that reported in developed
countries. The SMRs reported in hospital-based studies were
higher than those in community based studies probably owing to a
pattern of referral of more complex cases with intractable epilepsy
and a higher risk of death. Overall, few studies have been published
regarding mortality in Latin America. Interesting questions such as
a higher mortality rate of patients with epilepsy in Latin America
compared with other continents or regions cannot be supported
with the reported studies. The mortality reported in patients with
status epilepticus is similar to series of cases from other regions of
the world. More studies exploring speciﬁc causes of mortality are
needed as very little information has been published regarding
SUDEP and other causes of mortality in patients with epilepsy.
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Appendix
A.1. Search strategy
In EMBASE:
1. exp mortality/or exp death/or sudden infant death syndrome/or
(mortality or death or lethal* or fatal* or suicide or prognosis or
survival).mp.
A.L. Escalaya et al. / Seizure 25 (2015) 99–103 1032. exp ‘‘South and Central America’’/or exp Caribbean Islands/or
(‘‘south america’’ or ‘‘central america’’ or ‘‘latinamerica’’ or
caribbean).mp.
3. (Argentina or Bolivia or Brazil or Brasil or Chile or Colombia or
Ecuador or ‘‘French Guiana’’ or Guyana or Paraguay or Peru or
Suriname or Uruguay or Venezuela or Mexico or Belice or Belize
or ‘‘Costa Rica’’ or ‘‘El Salvador’’ or Guatemala or Honduras or
Nicaragua or Panama or ‘‘Antigua and Barbuda’’ or Aruba or
Bahamas or Barbados or ‘‘Cayman Islands’’ or Cuba or Curacao or
Dominica or ‘‘Dominican Republic’’ or Grenada or Guadeloupe or
Haiti or Jamaica or Martinique or Montserrat or ‘‘Netherlands
Antilles’’ or ‘‘Puerto Rico’’ or ‘‘Saint Barthelemy’’ or ‘‘Saint Kitts
and Nevis’’ or ‘‘Saint Martin’’ or ‘‘Saint Lucia’’ or ‘‘Saint Vincent
and the Grenadines’’ or ‘‘Turks Caicos Islands’’ or ‘‘Trinidad and
Tobago’’ or ‘‘Virgin Islands’’).mp. or Mexico/.
4. Exp epilepsy/or (epilep* or seizur*).mp.
5. 2 or 3.
6. 1 and 4.
7. 5 and 6.
In MEDLINE:
1. exp Mortality/or exp death/or (death or suicide or lethal* or
fatal* or mortality or prognosis or survival).mp.
2. Latin America/or exp South America/or expcentral America/or
exp Caribbean Region/or (latin America or south America or
central America or Caribbean).mp.
3. Mexico/or (Argentina or Bolivia or Brazil or Brasilor Chile or
Colombia or Ecuador or ‘‘French Guiana’’ or Guyana or Paraguay
or Peru or Suriname or Uruguay or Venezuela or Mexico or Belice
or Belize or ‘‘Costa Rica’’ or ‘‘El Salvador’’ or Guatemala or
Honduras or Nicaragua or Panama or ‘‘Antigua and Barbuda’’ or
Aruba or Bahamas or Barbados or Cayman Islands or Cuba
or Curacao or Dominica or ‘‘Dominican Republic’’ or Grenada or
Guadeloupe or Haiti or Jamaica or Martinique or Montserrat
or ‘‘Netherlands Antilles’’ or ‘‘Puerto Rico’’ or ‘‘Saint Barthelemy’’
or ‘‘Saint Kitts and Nevis’’ or ‘‘Saint Lucia’’ or ‘‘Saint Martin’’ or
‘‘Saint Vincent and the Grenadines’’ or ‘‘Trinidad and Tobago’’ or
‘‘Virgin Islands’’ or ‘‘Turks Caicos Islands’’).mp.
4. Exp Epilepsy/or (epilep* or seizur*).mp.
5. 2 or 3.
6. 1 and 4.
7. 5 and 6.
In LILACS:
epilep$ or seizur$ [Words] and mortality or death or fatal$ or
lethal$ or suicide or survival or prognosis [Words].References
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